Metabolic Disorders
Page 1 • 3 itemsUnlock global pharma market insights on metabolic disorders. Stay ahead with critical regulatory, R&D, and investment intelligence for BD and analysts.
Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Metabolic Disorder
Arrowhead Pharmaceuticals' REDEMPLO (plozasiran) receives Australian TGA approval for familial chylomicronemia syndrome, expanding global access.
NOVI Health's Hybrid Care Model Bridges GLP-1 Drug Efficacy Gap Between Clinical Trials and Real-World Outcomes
NOVI Health introduces hybrid care approach to improve real-world GLP-1 obesity drug outcomes that typically underperform compared to clinical trials.
SynbioTech's L. plantarum FS4722 Shows Promise for Hyperuricemia Prevention in Preclinical Studies
SynbioTech's probiotic strain L. plantarum FS4722 demonstrates potential for hyperuricemia prevention through gut-liver-kidney axis modulation in preclinical trials.